Pharmacogenomic Testing

"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.

Descriptor ID	D000071185
MeSH Number(s)	E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
Concept/Terms	Pharmacogenomic Testing Pharmacogenomic Testing Pharmacogenomic Testings Pharmacogenomic Screening Pharmacogenomic Screenings Pharmacogenetic Screening Pharmacogenetic Screenings Pharmacogenetic Testing Pharmacogenetic Testings Pharmacogenomic Analysis Pharmacogenomic Analysis Pharmacogenomic Analyses Pharmacogenetic Study Pharmacogenetic Studies Studies, Pharmacogenetic Pharmacogenetic Analysis Pharmacogenetic Analyses Pharmacogenomic Study Pharmacogenomic Studies

Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Genetic Testing [E01.370.225.562]
Pharmacogenomic Testing [E01.370.225.562.500]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Genetic Testing [E05.200.562]
Pharmacogenomic Testing [E05.200.562.500]
Genetic Techniques [E05.393]
Genetic Testing [E05.393.435]
Pharmacogenomic Testing [E05.393.435.500]
Health Care [N]
Health Care Facilities, Manpower, and Services [N02]
Health Services [N02.421]
Genetic Services [N02.421.308]
Genetic Testing [N02.421.308.430]
Pharmacogenomic Testing [N02.421.308.430.500]
Preventive Health Services [N02.421.726]
Diagnostic Services [N02.421.726.233]
Genetic Testing [N02.421.726.233.221]
Pharmacogenomic Testing [N02.421.726.233.221.500]

Below are MeSH descriptors whose meaning is related to "Pharmacogenomic Testing".

Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.

Bar chart showing 7 publications over 3 distinct years, with a maximum of 3 publications in 2019 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2019	1	2	3
2020	2	1	3
2021	1	0	1

Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.

Hertz DL, Arwood MJ, Stocco G, Singh S, Karnes JH, Ramsey LB. Planning and Conducting a Pharmacogenetics Association Study. Clin Pharmacol Ther. 2021 09; 110(3):688-701.

View in: PubMed
Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Brown K, Lewis D, Gutin A, Jablonski MR, Greden JF. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021 02; 296:113649.

View in: PubMed
Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Am J Geriatr Psychiatry. 2020 09; 28(9):933-945.

View in: PubMed
Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Macaluso M, Hain DT, Aguilar AL, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Res. 2020 08; 290:113017.

View in: PubMed
Singh S, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.

View in: PubMed
Patel RC, Stalter RM, Thomas KK, Tamraz B, Blue SW, Erikson DW, Kim CJ, Kelly EJ, Nanda K, Kourtis AP, Lingappa JR, Mugo N, Baeten JM, Scarsi KK. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. AIDS. 2019 11 01; 33(13):1995-2004.

View in: PubMed
Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 04; 111:59-67.

View in: PubMed

People

Explore

Similar Concepts

Top Journals